Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1678-1687

  Sahin, Erinc ^a,c   Weiss, William F ^a,d   Kroetsch, Andrew M ^a,c   King, Kevin R ^b   Kessler, R Kendall ^b   Das, Tapan K ^b   Roberts, Christopher J ^a  

^a University of Delaware   (United States)

^b PFIZER INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Biotechnology; Calorimetry (DSC); Physical stability; Protein aggregation; Solubility

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2 ANTIBODY; MONOCLONAL ANTIBODY; OLIGOMER; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOGLOBULIN G;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; GEL PERMEATION CHROMATOGRAPHY; IMMUNOGLOBULIN AGGREGATE; LASER; LIGHT SCATTERING; PH; PROTEIN STABILITY; SOLUBILITY; TEMPERATURE; IMMUNOLOGY; KINETICS;

ANTIBODIES; CALORIMETRY, DIFFERENTIAL SCANNING; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; KINETICS; SOLUBILITY; TEMPERATURE;

EID: 84864298532     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23056     Document Type: Article

References (35)

1. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289(1-2):1-30.
2. Weiss WF IV, Young TM, Roberts CJ. 2009. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98(4):1246-1277.
3. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):2909-2934.
4. Das TK, Nema S. 2008. Protein particulate issues in biologics development. Am Pharm Rev 11(4):52-57.
5. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98(5):927-938.
6. Kiese S, Pappenberger A, Friess W, Mahler HC. 2009. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation. J Pharm Sci 99(2):632-644.
7. Perico N, Purtell J, Dillon TM, Ricci MS. 2009. Conformational implications of an inversed pH-dependent antibody aggregation. J Pharm Sci 98(9):3031-3042.
8. Roberts CJ, Darrington RT, Whitley MB. 2003. Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92(5):1095-1111.
9. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 99:4830-4848.
10. Andrews JM, Weiss WF IV, Roberts CJ. 2008. Nucleation, growth, and activation energies for seeded and unseeded aggregation of alpha-chymotrypsinogen A. Biochemistry 47(8):2397-2403.
11. Bajaj H, Sharma VK, Badkar A, Zeng D, Nema S, Kalonia DS. 2006. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution. Pharm Res 23(6):1382-1394.
12. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
13. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. 2005. Solution behavior of IFN-beta-1a: An empirical phase diagram based approach. J Pharm Sci 94(9):1893-1911.
14. Li Y, Ogunnaike BA, Roberts CJ. 2010. Multi-variate approach to global protein aggregation behavior and kinetics: Effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. J Pharm Sci 99(2):645-662.
15. Uversky VN, Fink AL. 2004. Conformational constraints for amyloid fibrillation: The importance of being unfolded. Biochim Biophys Acta 1698(2):131-153.
16. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289(1-2):1-30.
17. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435(7043):773-778.
18. Wiltzius JJ, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D. 2008. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Sci 17(9):1467-1474.
19. Wang X, Das TK, Singh SK, Kumar S. 2009. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs 1(3):254-267.
20. Bartkowski R, Kitchel R, Peckham N, Margulis L. 2002. Aggregation of recombinant bovine granulocyte colony stimulating factor in solution. J Protein Chem 21(3):137-143.
21. Li Y, Weiss WF IV, Roberts CJ. 2009. Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. J Pharm Sci 98(11):3997-4016.
22. Andrews JM, Roberts CJ. 2007. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J Phys Chem B 111(27):7897-7913.
23. Khandpur RS. 2006. Handbook of analytical instruments. 2 ed. New Delhi: Tata McGraw-Hill.
24. Anisimov MA. 1991. Critical phenomena in liquids and liquid crystals. Amsterdam: Gordon and Breach Science Publishers.
25. Vermeer AWP, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78(1):394-404.
26. Lyubarev A, Kurganov B. 2000. Analysis of DSC data relating to proteins undergoing irreversible thermal denaturation. J Thermal Anal Calorimetry 62(1):51-62.
27. Sanchez-Ruiz JM, Lopez-Lacomba JL, Cortijo M, Mateo PL. 1988. Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry 27(5):1648-1652.
28. Vermeer AWP, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78(1):394-404.
29. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97(4):1414-1426.
30. Garber E, Demarest SJ. 2007. A broad range of Fab stabilities within a host of therapeutic lgGs. Biochem Biophys Res Comm 355(3):751-757.
31. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 99(11):4830-4848.
32. Brummitt RK, Nesta DP, Chang L, Chase SF, Laue TM, Roberts CJ. 2011. Non-native aggregation of an IGG1 antibody in acidic conditions: 1. Unfolding, colloidal interactions, and high molecular weight aggregate formation. J Pharm Sci 100(6):2087-2103.
33. Sek D, Luisi D, Warne N. 2008. Polyol-induced increases in thermal stability of antibodies by DSC. Pharm Rev 11:44-46.
34. Brandts JF, Hu CQ, Lin LN, Mos MT. 1989. A simple model for proteins with interacting domains. Applications to scanning calorimetry data. Biochemistry 28:8588-8596.
35. Brummitt RK, Nesta DP, Chang L, Kroetsch AM, Roberts CJ. 2011. Non-native aggregation of an IgG1 antibody in acidic conditions: 2. Nucleation-and-growth kinetics with competing growth mechanisms. J Pharm Sci 100:2104-2119.